CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
gene-therapy
gene-therapy coverage curates 3 recent articles on investor moves, stock trends, and CRISPR news to help you evaluate biotech opportunities and protect your portfolio.
3 articles
Is This Biotech Stock After Groundbreaking Approval?
A breakthrough approval can move a biotech stock in dramatic ways. This guide breaks down how to assess the upside, m...
Biotech Investor Adds Million as Krystal Biotech Revenue Rises
A major biotech investor is stepping up its bet on Krystal Biotech as the company posts robust 2025 revenue. This mov...